Cargando…

Development and validation of a prognostic 9-gene signature for colorectal cancer

INTRODUCTION: Colorectal cancer (CRC) is one of the most prevalent cancers globally with a high mortality rate. Predicting prognosis using disease progression and cancer pathologic stage is insufficient, and a prognostic factor that can accurately evaluate patient prognosis needs to be developed. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Junpeng, Guo, Fangyu, Yu, Yifan, Ma, Zihuan, Hong, Yuting, Su, Junyan, Ge, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714635/
https://www.ncbi.nlm.nih.gov/pubmed/36465397
http://dx.doi.org/10.3389/fonc.2022.1009698
_version_ 1784842272890683392
author Cui, Junpeng
Guo, Fangyu
Yu, Yifan
Ma, Zihuan
Hong, Yuting
Su, Junyan
Ge, Yang
author_facet Cui, Junpeng
Guo, Fangyu
Yu, Yifan
Ma, Zihuan
Hong, Yuting
Su, Junyan
Ge, Yang
author_sort Cui, Junpeng
collection PubMed
description INTRODUCTION: Colorectal cancer (CRC) is one of the most prevalent cancers globally with a high mortality rate. Predicting prognosis using disease progression and cancer pathologic stage is insufficient, and a prognostic factor that can accurately evaluate patient prognosis needs to be developed. In this study, we aimed to infer a prognostic gene signature to identify a functional signature associated with the prognosis of CRC patients. METHODS: First, we used univariate Cox regression, least absolute shrinkage and selection operator (lasso) regression, and multivariate Cox regression analyses to screen genes significantly associated with CRC patient prognosis, from colorectal cancer RNA sequencing data in The Cancer Genome Atlas (TCGA) database. We then calculated the risk score (RS) for each patient based on the expression of the nine candidate genes and developed a prognostic signature. RESULTS: Based on the optimal cut-off on the receiver operating characteristic (ROC) curve, patients were separated into high- and low-risk groups, and the difference in overall survival between the two groups was examined. Patients in the low-risk group had a better overall survival rate than those in the high-risk group. The results were validated using the GSE72970, GSE39582, and GSE17536 Gene Expression Omnibus (GEO) datasets, and the same conclusions were reached. ROC curve test of the RS signature also indicated that it had excellent accuracy. The RS signature was then compared with traditional clinical factors as a prognostic indicator, and we discovered that the RS signature had superior predictive ability. CONCLUSION: The RS signature developed in this study has excellent predictive power for the prognosis of patients with CRC and broad applicability as a prognostic indicator for patients.
format Online
Article
Text
id pubmed-9714635
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97146352022-12-02 Development and validation of a prognostic 9-gene signature for colorectal cancer Cui, Junpeng Guo, Fangyu Yu, Yifan Ma, Zihuan Hong, Yuting Su, Junyan Ge, Yang Front Oncol Oncology INTRODUCTION: Colorectal cancer (CRC) is one of the most prevalent cancers globally with a high mortality rate. Predicting prognosis using disease progression and cancer pathologic stage is insufficient, and a prognostic factor that can accurately evaluate patient prognosis needs to be developed. In this study, we aimed to infer a prognostic gene signature to identify a functional signature associated with the prognosis of CRC patients. METHODS: First, we used univariate Cox regression, least absolute shrinkage and selection operator (lasso) regression, and multivariate Cox regression analyses to screen genes significantly associated with CRC patient prognosis, from colorectal cancer RNA sequencing data in The Cancer Genome Atlas (TCGA) database. We then calculated the risk score (RS) for each patient based on the expression of the nine candidate genes and developed a prognostic signature. RESULTS: Based on the optimal cut-off on the receiver operating characteristic (ROC) curve, patients were separated into high- and low-risk groups, and the difference in overall survival between the two groups was examined. Patients in the low-risk group had a better overall survival rate than those in the high-risk group. The results were validated using the GSE72970, GSE39582, and GSE17536 Gene Expression Omnibus (GEO) datasets, and the same conclusions were reached. ROC curve test of the RS signature also indicated that it had excellent accuracy. The RS signature was then compared with traditional clinical factors as a prognostic indicator, and we discovered that the RS signature had superior predictive ability. CONCLUSION: The RS signature developed in this study has excellent predictive power for the prognosis of patients with CRC and broad applicability as a prognostic indicator for patients. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9714635/ /pubmed/36465397 http://dx.doi.org/10.3389/fonc.2022.1009698 Text en Copyright © 2022 Cui, Guo, Yu, Ma, Hong, Su and Ge https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cui, Junpeng
Guo, Fangyu
Yu, Yifan
Ma, Zihuan
Hong, Yuting
Su, Junyan
Ge, Yang
Development and validation of a prognostic 9-gene signature for colorectal cancer
title Development and validation of a prognostic 9-gene signature for colorectal cancer
title_full Development and validation of a prognostic 9-gene signature for colorectal cancer
title_fullStr Development and validation of a prognostic 9-gene signature for colorectal cancer
title_full_unstemmed Development and validation of a prognostic 9-gene signature for colorectal cancer
title_short Development and validation of a prognostic 9-gene signature for colorectal cancer
title_sort development and validation of a prognostic 9-gene signature for colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714635/
https://www.ncbi.nlm.nih.gov/pubmed/36465397
http://dx.doi.org/10.3389/fonc.2022.1009698
work_keys_str_mv AT cuijunpeng developmentandvalidationofaprognostic9genesignatureforcolorectalcancer
AT guofangyu developmentandvalidationofaprognostic9genesignatureforcolorectalcancer
AT yuyifan developmentandvalidationofaprognostic9genesignatureforcolorectalcancer
AT mazihuan developmentandvalidationofaprognostic9genesignatureforcolorectalcancer
AT hongyuting developmentandvalidationofaprognostic9genesignatureforcolorectalcancer
AT sujunyan developmentandvalidationofaprognostic9genesignatureforcolorectalcancer
AT geyang developmentandvalidationofaprognostic9genesignatureforcolorectalcancer